skip to content

Early Cancer Institute

  • Group Leader, Early Cancer Institute, University of Cambridge
  • UK Research and Innovation Future Leaders Fellow, University of Cambridge


Siddhartha studied medicine at the Byramjee Jeejeebhoy Government Medical College and trained at the Sassoon General Hospitals in Pune, India. He holds an MPH degree from the University of Texas at Houston in the US and a PhD from the University of Cambridge in the UK, where he was a Gates Cambridge Scholar between 2012 and 2015. His scientific training has also included research stints at the MD Anderson Cancer Center in Houston, Texas (2010-2012) and as a Junior Research Fellow of Homerton College, Cambridge (2015-2019). Siddhartha was awarded a Future Leaders Fellowship by UKRI in 2020 that enabled him to establish his independent research group within the Medical Research Council (MRC) Integrative Epidemiology Unit at the University of Bristol. He returned to Cambridge as a Group Leader at the Early Cancer Institute in the Department of Oncology in March 2023.


With the support of funding from UK Research and Innovation and Cancer Research UK, the Kar group primarily studies inherited or germline genetic variation and leverages this variation to investigate the causes, consequences, and correlates of key somatic or tumour genomic aberrations responsible for driving cancer development and progression. The ultimate aim is to use insights from this work to inform the prevention, early detection and treatment of common cancers.

The group is also involved in the search for inherited genetic risk factors that are pleiotropic or shared across some of the major hormone-related cancer types -- specifically breast, prostate, ovarian, and endometrial cancers -- and also shared between cancers and their risk factors. Cross-cancer pleiotropic genome-wide association studies may offer unique opportunities to build multi-cancer risk prediction and stratification tools to better target early detection interventions. This aspect of the group’s work is funded by a five-year R01 grant awarded in 2022 by the US National Institutes of Health (NIH) on which Siddhartha serves as one of three principal investigators (PIs), and is the only PI based outside the US.